Literature DB >> 11160742

Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.

A L Adamson1, S Kenney.   

Abstract

Although the immediate-early proteins of both herpes simplex virus (HSV) and cytomegalovirus (CMV) are known to modify promyelocytic leukemia (PML) (ND10) bodies in the nucleus of the host cell, it has been unclear whether lytic infection with gamma herpesviruses induces a similar effect. The PML protein is induced by interferon, involved in major histocompatibility complex class I presentation, and necessary for certain types of apoptosis. Therefore, it is likely that PML bodies function in an antiviral capacity. SUMO-1 modification of PML is known to be required for the formation of PML bodies. To examine whether Epstein-Barr virus (EBV) lytic replication interferes with PML bodies, we expressed the EBV immediate-early genes BZLF1 (Z) and BRLF1 (R) in EBV-positive cell lines and examined PML localization. Both Z and R expression resulted in PML dispersion in EBV-positive cells. Z but not R expression is sufficient to disrupt PML bodies in EBV-negative cell lines. We show that dispersion of PML bodies by Z requires a portion of the transcriptional activation domain of Z but not the DNA-binding function. As was previously reported for the HSV-1 ICP0 and CMV IE1 proteins, Z reduces the amount of SUMO-1-modified PML. We also found that Z itself is SUMO-1 modified (through amino acid 12) and that Z competes with PML for limiting amounts of SUMO-1. These results suggest that disruption of PML bodies is important for efficient lytic replication of EBV. Furthermore, Z may potentially alter the function of a variety of cellular proteins by inhibiting SUMO-1 modification.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160742      PMCID: PMC114822          DOI: 10.1128/JVI.75.5.2388-2399.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  86 in total

1.  Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.

Authors:  S Müller; A Dejean
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.

Authors:  A Melnick; J D Licht
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

3.  The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper.

Authors:  T Kouzarides; G Packham; A Cook; P J Farrell
Journal:  Oncogene       Date:  1991-02       Impact factor: 9.867

4.  Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required.

Authors:  J F Giot; I Mikaelian; M Buisson; E Manet; I Joab; J C Nicolas; A Sergeant
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

5.  The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.

Authors:  S C Kenney; E Holley-Guthrie; E B Quinlivan; D Gutsch; Q Zhang; T Bender; J F Giot; A Sergeant
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

6.  Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia.

Authors:  A D Goddard; J Borrow; P S Freemont; E Solomon
Journal:  Science       Date:  1991-11-29       Impact factor: 47.728

7.  Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis.

Authors:  C Szostecki; H H Guldner; H J Netter; H Will
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

8.  The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.

Authors:  H de Thé; C Lavau; A Marchio; C Chomienne; L Degos; A Dejean
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

9.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.

Authors:  A Kakizuka; W H Miller; K Umesono; R P Warrell; S R Frankel; V V Murty; E Dmitrovsky; R M Evans
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

10.  Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties.

Authors:  P P Pandolfi; F Grignani; M Alcalay; A Mencarelli; A Biondi; F LoCoco; F Grignani; P G Pelicci
Journal:  Oncogene       Date:  1991-07       Impact factor: 9.867

View more
  135 in total

Review 1.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  HPV E6 proteins target Ubc9, the SUMO conjugating enzyme.

Authors:  Phillip R Heaton; Adeline F Deyrieux; Xue-Lin Bian; Van G Wilson
Journal:  Virus Res       Date:  2011-04-12       Impact factor: 3.303

3.  SUMOylation of the human cytomegalovirus 72-kilodalton IE1 protein facilitates expression of the 86-kilodalton IE2 protein and promotes viral replication.

Authors:  Michael Nevels; Wolfram Brune; Thomas Shenk
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

5.  Epstein-Barr virus LF2 protein regulates viral replication by altering Rta subcellular localization.

Authors:  Andreas M F Heilmann; Michael A Calderwood; Eric Johannsen
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

6.  Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.

Authors:  Amy L Ellis; Zhenxun Wang; Xianming Yu; Janet E Mertz
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

7.  Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.

Authors:  Tawin Iempridee; Jessica A Reusch; Andrew Riching; Eric C Johannsen; Sinisa Dovat; Shannon C Kenney; Janet E Mertz
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.

Authors:  Y Xu; J H Ahn; M Cheng; C M apRhys; C J Chiou; J Zong; M J Matunis; G S Hayward
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  The SP100 component of ND10 enhances accumulation of PML and suppresses replication and the assembly of HSV replication compartments.

Authors:  Pei Xu; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

10.  Modeling early Epstein-Barr virus infection in Drosophila melanogaster: the BZLF1 protein.

Authors:  Amy L Adamson; Natasha Wright; Dennis R LaJeunesse
Journal:  Genetics       Date:  2005-08-03       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.